Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease

International Psychogeriatrics

Volumn 22, Issue 6, 2010, Pages 966-972

  Horstmann, Solveig ^a   Budig, Leila ^a   Gardner, Humphrey ^d   Koziol, James ^b   Deuschle, Michael ^c   Schilling, Claudia ^c   Wagner, Simone ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d NOVARTIS   (United States)

Author keywords

Alzheimer's disease; dementia; matrix metalloproteinases

Indexed keywords

CASEIN; GELATIN; GELATINASE A; GELATINASE B; STROMELYSIN; STROMELYSIN 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; ZYMOGRAPHY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MENTAL STATUS SCHEDULE; MIDDLE AGED; REFERENCE VALUES;

EID: 77957321489     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610210000827     Document Type: Article

References (30)

1. Adair, J. C. et al. (2004). Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke, 35, e159-162.
2. Alvarez-Sabin, J. et al. (2004). Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke, 35, 1316-22.
3. Backstrom, J. R., Lim, G. P., Cullen, M. J. and Tokes, Z. A. (1996). Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). Journal of Neuroscience, 16, 79101-799.
4. Bar-Or, A. et al. (2003). Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain, 126, 2738-2749.
5. Beuche, W., Yushchenko, M., Mader, M., Maliszewska, M., Felgenhauer, K. and Weber, F. (2000). Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport, 11, 3419-3422.
6. Beyzade, S., Zhang, S., Wong, Y. K., Day, I. N., Eriksson, P. and Ye, S. (2003). Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. Journal of the American College of Cardiology, 41, 2130-2137.
7. Campbell, I. L. and Pagenstecher, A. (1999). Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic. Trends in Neurosciences, 22, 285-287.
8. Deb, S., Wenjun Zhang, J. and Gottschall, P. E. (2003). Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Research, 970, 205-213.
9. Flex, A. et al. (2006). Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 61, 1065-1069.
10. Helbecque, N., Hermant, X., Cottel, D. and Amouyel, P. (2003). The role of matrix metalloproteinase-9 in dementia. Neuroscience Letters, 350, 181-183.
11. Helbecque, N., Cottel, D., Hermant, X. and Amouyel, P. (2007). Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiology of Aging, 28, 1215-1220.
12. Hofman, A. et al. (1997). Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet, 349, 151-154. (Pubitemid 27039193)
13. Horstmann, S., Kalb, P., Koziol, J., Gardner, H. and Wagner, S. (2003). Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke, 34, 2165-2170.
14. Lorenzl, S. et al. (2003a). Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. Journal of the Neurological Science, 207, 71-76.
15. Lorenzl, S. et al. (2003b). Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 43, 191-196.
16. Lorenzl, S., Buerger, K., Hampel, H. and Beal, M. F. (2008). Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics, 20, 67-76.
17. Martin-Aragon, S. et al. (2009). Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochemical Research, 34, 373-378.
18. McGeer, E. G. and McGeer, P. L. (1998). The importance of inflammatory mechanisms in Alzheimer disease. Experimental Gerontology, 33, 371-378.
19. Montaner, J. et al. (2001). Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke, 32, 1759-1766.
20. Mrak, R. E. and Griffin, W. S. (2007). Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 66, 683-686.
21. Pollanen, P. J. et al. (2002). Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis, 164, 329-335.
22. Pollanen, P. J. et al. (2005). Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis, 180, 73-78.
23. Pozzi, A., Moberg, P. E., Miles, L. A., Wagner, S., Soloway, P. and Gardner, H. A. (2000). Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proceedings of the National Academies of Sciences, 97, 2202-2207.
24. Reitz, C. et al. (2008). Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease: the Rotterdam Study. Neurobiology of Aging, 29, 874-881.
25. Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J. and Fridman, R. (1994). Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochemical and Biophysical Research Communication, 205, 1755-1761
26. Saarela, M. S. et al. (2004). Interaction between matrix metalloproteinase 3 and the epsilon4 allele of apolipoprotein E increases the risk of Alzheimer's disease in Finns. Neuroscience Letters, 367, 336-339.
27. Thorns, V., Walter, G. F. and Thorns, C. (2003). Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Research, 23, 3937-3944.
28. White, A. R. et al. (2006). Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. Journal of Biological Chemistry, 281, 17670-17680.
29. Woessner, J. F., Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB Journal, 5, 2145-2154.
30. Yoshiyama, Y., Asahina, M. and Hattori, T. (2000). Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathologica, 99, 91-95.